Yousif Capital Management LLC Trims Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Yousif Capital Management LLC trimmed its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 2.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 20,727 shares of the specialty pharmaceutical company’s stock after selling 504 shares during the period. Yousif Capital Management LLC’s holdings in Supernus Pharmaceuticals were worth $679,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Raiffeisen Bank International AG purchased a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at approximately $25,000. Financial Management Professionals Inc. bought a new position in Supernus Pharmaceuticals during the 1st quarter valued at approximately $30,000. Versant Capital Management Inc raised its stake in Supernus Pharmaceuticals by 6,931.3% during the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company’s stock valued at $37,000 after buying an additional 1,109 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in Supernus Pharmaceuticals during the fourth quarter valued at $42,000. Finally, Smartleaf Asset Management LLC boosted its holdings in Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 870 shares in the last quarter.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on SUPN. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th. Wall Street Zen cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday.

Supernus Pharmaceuticals Trading Down 2.1%

NASDAQ:SUPN opened at $32.28 on Friday. The business’s 50-day moving average is $32.14 and its 200 day moving average is $34.21. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.55 and a 12 month high of $40.28. The company has a market capitalization of $1.81 billion, a P/E ratio of 29.08 and a beta of 0.71.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.